Brad Kahl

Research output

Research output per year 1997 2014 2016 2017 2018 2019 2020 2022 2023 2024 2024

• 201 Article
• 47 Review article
• 29 Letter
• 9 Comment/debate
• 8 More
  • 7 Editorial
  • 1 Chapter

Research output per year

Research output per year

Search results

• 2024

  A phase II study of interrupted and continuous dose lenalidomide in relapsed/refractory Hodgkin lymphoma

  Fehniger, T. A., Watkins, M. P., Ezenwajiaku, N., Wan, F., Hurd, D. D., Cashen, A. F., Blum, K. A., Goy, A., Fenske, T. S., Wagner-Johnston, N. D., Carson, K., Siegel, M. J., Russler-Germain, D., Schneider, S. E., Mehta-Shah, N., Kahl, B. & Bartlett, N. L., Mar 2024, In: Haematologica. 109, 3, p. 953-957 5 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• Characterization of zanubrutinib safety and tolerability profile and comparison with ibrutinib safety profile in patients with B-cell malignancies: post hoc analysis of a large clinical trial safety database

  Brown, J. R., Ghia, P., Jurczak, W., Kahl, B. S., Lamanna, N., Robak, T., Shadman, M., Tam, C. S., Qiu, L., Paik, J., Salmi, T., Wang, L., Zhang, J., Zhang, M., Cohen, A., Ma, H. & Tedeschi, A., Jul 2024, In: Haematologica. 109, 7, p. 2277-2283 7 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access
  1 Scopus citations
• 2022

  COVID-19 booster vaccines generate seroconversion in subset of patients with lymphoma/CLL: single institution experience

  Mehta-Shah, N., Bartlett, N. L., Kahl, B., Watkins, M. P., Dubois, A., Schmelzle, G., Waqar, S., Ballman, C., Wan, F. & Farnsworth, C. W., 2022, In: Leukemia and Lymphoma. 63, 7, p. 1723-1727 5 p.

  Research output: Contribution to journal › Letter › peer-review
  1 Scopus citations

• Extranodal presentation in limited-stage diffuse large B-cell lymphoma as a prognostic marker in three SWOG trials S0014, S0313 and S1001

  Stephens, D. M., Li, H., Constine, L. S., Fitzgerald, T. J., Leonard, J. P., Kahl, B. S., Song, J. Y., LeBlanc, M. L., Smith, S. M., Persky, D. O. & Friedberg, J. W., Nov 2022, In: Haematologica. 107, 11, p. 2732-2736 5 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access
  2 Scopus citations

• Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study

  Alderuccio, J. P., Ai, W. Z., Radford, J., Solh, M., Ardeshna, K. M., Lunning, M. A., Hess, B. T., Zinzani, P. L., Stathis, A., Carlo-Stella, C., Hamadani, M., Kahl, B. S., Ungar, D., Kilavuz, T., Yu, E., Qin, Y. & Caimi, P. F., Aug 23 2022, In: Blood Advances. 6, 16, p. 4736-4739 4 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access
  2 Scopus citations

• Long-term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow-up

  Dreyling, M., Goy, A., Hess, G., Kahl, B. S., Hernández-Rivas, J. Á., Schuier, N., Qi, K., Deshpande, S., Zhu, A., Parisi, L. & Wang, M. L., May 13 2022, In: HemaSphere. 6, 5, p. E712

  Research output: Contribution to journal › Letter › peer-review

  Open Access
  28 Scopus citations
• 2019

  Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: Extended 3.5-year follow up from a pooled analysis

  Rule, S., Dreyling, M., Goy, A., Hess, G., Auer, R., Kahl, B., Hernández-Rivas, J. Á., Qi, K., Deshpande, S., Parisi, L. & Wang, M., Apr 30 2019, In: Haematologica. 104, 5, p. e211-e214

  Research output: Contribution to journal › Letter › peer-review

  Open Access
  124 Scopus citations
• 2018

  Another plenary, more uncertainty

  Kahl, B. S., Jan 2018, In: Clinical Advances in Hematology and Oncology. 16, 1, p. 6 1 p.

  Research output: Contribution to journal › Letter › peer-review

• Mentoring

  Kahl, B. S., Apr 2018, In: Clinical Advances in Hematology and Oncology. 16, 4, p. 234 1 p.

  Research output: Contribution to journal › Letter › peer-review

• More CRO fun

  Kahl, B. S., May 2018, In: Clinical Advances in Hematology and Oncology. 16, 5, p. 304 1 p.

  Research output: Contribution to journal › Letter › peer-review

• Narcissist-in-chief

  Kahl, B. S., Feb 2018, In: Clinical Advances in Hematology and Oncology. 16, 2, p. 74 1 p.

  Research output: Contribution to journal › Letter › peer-review

• On relevance

  Kahl, B. S., Oct 2018, In: Clinical Advances in Hematology and Oncology. 16, 10, p. 634 1 p.

  Research output: Contribution to journal › Letter › peer-review

• The fast-changing world of CLL

  Kahl, B. S., Jun 2018, In: Clinical Advances in Hematology and Oncology. 16, 6, p. 396 1 p.

  Research output: Contribution to journal › Letter › peer-review

• Trivia night

  Kahl, B. S., Mar 2018, In: Clinical Advances in Hematology and Oncology. 16, 3, p. 159 1 p.

  Research output: Contribution to journal › Letter › peer-review

• With a little help from my friends

  Kahl, B. S., Dec 2018, In: Clinical Advances in Hematology and Oncology. 16, 12, p. 776 1 p.

  Research output: Contribution to journal › Letter › peer-review
• 2017

  Affordable care?

  Kahl, B. S., Apr 2017, In: Clinical Advances in Hematology and Oncology. 15, 4, p. 227 1 p.

  Research output: Contribution to journal › Letter › peer-review

• ASCO cage match: BR vs R-CHOP

  Kahl, B. S., Jul 2017, In: Clinical Advances in Hematology and Oncology. 15, 7, p. 502 1 p.

  Research output: Contribution to journal › Letter › peer-review

• Book club: The Panama canal

  Kahl, B. S., Sep 2017, In: Clinical Advances in Hematology and Oncology. 15, 9, p. 651 1 p.

  Research output: Contribution to journal › Letter › peer-review

• Buyer beware!

  Kahl, B. S., May 2017, In: Clinical Advances in Hematology and Oncology. 15, 5, p. 318 1 p.

  Research output: Contribution to journal › Letter › peer-review

• Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: A subgroup analysis of a phase 2 study

  Salles, G., Schuster, S. J., De Vos, S., Wagner-Johnston, N. D., Viardot, A., Blum, K. A., Flowers, C. R., Jurczak, W. J., Flinn, I. W., Kahl, B. S., Martin, P., Kim, Y., Shreay, S., Will, M., Sorensen, B., Breuleux, M., Zinzani, P. L. & Gopal, A. K., Mar 31 2017, In: Haematologica. 102, 4, p. e156-e159

  Research output: Contribution to journal › Letter › peer-review

  Open Access
  66 Scopus citations

• How to treat Hodgkin lymphoma

  Kahl, B. S., Oct 2017, In: Clinical Advances in Hematology and Oncology. 15, 10, p. 722 1 p.

  Research output: Contribution to journal › Letter › peer-review

• In memory of Oliver press, MD. PhD

  Kahl, B. S., Nov 2017, In: Clinical Advances in Hematology and Oncology. 15, 11, p. 806 1 p.

  Research output: Contribution to journal › Letter › peer-review

• Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by ⁹⁰Y-ibritumomab tiuxetan: 10-year follow-up of the phase 2 ECOG-ACRIN study E1499

  Smith, M. R., Hong, F., Li, H., Gordon, L. I., Gascoyne, R. D., Paietta, E. M., Advani, R. H., Forero-Torres, A., Horning, S. J. & Kahl, B. S., Feb 1 2017, In: Leukemia. 31, 2, p. 517-519 3 p.

  Research output: Contribution to journal › Letter › peer-review
  14 Scopus citations

• NR4A1 inhibition synergizes with ibrutinib in killing mantle cell lymphoma cells

  Li, Y., Wang, F., Lu, L., Zhu, F., Huang, S., Nomie, K., Zhang, L., Yang, D. T., Huang, W., Kahl, B. S., Safe, S., Wang, M. & Rui, L., Dec 1 2017, In: Blood cancer journal. 7, 12, 32.

  Research output: Contribution to journal › Letter › peer-review

  Open Access
  3 Scopus citations

• Protests

  Kahl, B. S., Dec 2017, In: Clinical Advances in Hematology and Oncology. 15, 12, p. 892 1 p.

  Research output: Contribution to journal › Letter › peer-review

• Take back the research

  Kahl, B. S., Aug 2017, In: Clinical Advances in Hematology and Oncology. 15, 8, p. 567 1 p.

  Research output: Contribution to journal › Letter › peer-review

• The ASH rehash

  Kahl, B. S., Jan 2017, In: Clinical Advances in Hematology and Oncology. 15, 1, p. 7 1 p.

  Research output: Contribution to journal › Letter › peer-review

• When will we beat R-CHOP?

  Kahl, B. S., Mar 2017, In: Clinical Advances in Hematology and Oncology. 15, 3, p. 159 1 p.

  Research output: Contribution to journal › Letter › peer-review
• 2012

  Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial

  Advani, R. H., Hong, F., Horning, S. J., Kahl, B. S., Manola, J., Swinnen, L. J., Habermann, T. M. & Ganjoo, K., Apr 2012, In: Leukemia and Lymphoma. 53, 4, p. 718-720 3 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access
  24 Scopus citations